💨 Abstract

Syed Khalid Ali, Chief Scientific Officer of Panacea Biotec, marks August 14, 2024, as a significant day when the first participant from Rohtak, Haryana, was enrolled in Phase-III trials of India's first indigenous dengue vaccine, DengiAll. This vaccine, developed over 15 years, targets all four dengue serotypes with a single dose, addressing the limitations of existing vaccines.

Courtesy: theprint.in